Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Maksim Shlykov

Orthopaedic Surgery of the Spine Baltimore, MD Medical Doctor

NPI 1104346337 CMS profile 2975399

301 Saint Paul St, Baltimore, MD 21202

Open in the dashboard

General payments

$13,898

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maksim Shlykov of Baltimore, MD is reported in the CMS Open Payments database as having received $13,898 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,184 22
2024 General $870 14
2023 General $5,076 37
2022 General $4,428 24
2021 General $335 2
2020 General $340 2
2019 General $666 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maksim Shlykov
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Maksim Shlykov were reported at $2,184. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Maksim Shlykov Orthopaedic Surgery of the Spine median Middle half National median
2019 $666 $2,106 $337–$18,608 $163
2020 $340 $1,213 $156–$15,082 $114
2021 $335 $1,834 $271–$15,617 $132
2022 $4,428 $2,015 $320–$17,036 $149
2023 $5,076 $1,925 $336–$14,599 $160
2024 $870 $2,110 $341–$12,483 $164
2025 $2,184 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Globus Medical, Inc. $5,276 26 payments
  2. Medtronic, Inc. $2,098 24 payments
  3. Stryker Corporation $1,228 9 payments
  4. Smaio SA $1,089 5 payments
  5. Medical Device Business Services, Inc. $1,025 6 payments
  6. Highridge Medical LLC $869 6 payments
  7. DePuy Synthes Sales Inc. $552 10 payments
  8. SI-BONE, Inc. $447 3 payments
  9. Boston Scientific Corporation $203 2 payments
  10. Augmedics Inc. $165 1 payment
  11. Other $947 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,834 86 payments
  2. Travel and Lodging $6,020 15 payments
  3. Education $1,025 6 payments
  4. Entertainment $20 1 payment
Products named General payments · program years 2019–2025
  1. SABLE $2,063 3 payments
  2. QUARTEX $1,607 5 payments
  3. EVEREST SPINAL SYSTEM $1,208 9 payments
  4. Xvision $823 5 payments
  5. CD HORIZON SPINAL SYSTEM $733 9 payments
  6. Vital $486 2 payments
  7. Senza $375 4 payments
  8. ExcelsiusGPS Robotic Navigation System $349 4 payments
  9. MAZOR X SYSTEM $330 3 payments
  10. Excelsius Robotics System $255 3 payments
  11. Other $4,167 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

750

Median for Orthopedic Surgery: 203

Drug cost

$4,432

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 178 $1,211
Cyclobenzaprine Hcl Generic 196 $1,174
Gabapentin Generic 247 $1,160
Pregabalin Generic 40 $349
Meloxicam Generic 55 $328
Baclofen Generic 14 $143
Methocarbamol Generic 20 $68

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$180,823

Medicare's payments for the services billed

Medicare patients

479

Average age 73

Services billed

1,155

298 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 33%
Ischemic heart disease 28%
Depression 28%
Osteoporosis 24%
Chronic kidney disease 20%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record